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Flynn and Buchanan-found 65 reported cases of renal artery anomalies with neurofibromatosis in the literature and added a female patient (46 years) with bilateral saccular aneurysms of renal arteries resulting in hypertension. Fienman and Yakovac" described hypertension and vascular lesions in 4 out of 46 children with neurofibromatosis.
Many authors have described plexiform neurofibromas in the adventitia of the involved renal artery':". Histopathologically the lesions are offour types -pure intimal, advanced intimal, intimal aneurysmal and peri-arterial nodular. Tapp and Hickling" described a 35-year-old pregnant woman who was diagnosed as leaking aortic aneurysm but on autopsy was found to have a renal artery aneurysm rupture on the right side.
Sousson et at.7 have presented various operative procedures to repair renal aneurysm.
The most likely cause of hypertension in neurofibromatosis is pheochromocytoma but renal artery lesions must not be overlooked. Psittacosis, an uncommon 'atypical pneumonia' is caused by Chlamydia psittaci, an obligate intracellular parasite closely related to gram negative bacteria. The infection is systemic and the illness varies from a mild to severe pneumonia with multisystem disease'. Cardiac involvement is a known complication and several cases of embolic phenomena to peripheral arteries have been described>". We report a case which presented as a major arterial embolus to the right leg where there was no clinical evidence of cardiac involvement.
Case report
A 42-year-old man was admitted with a 24 h history of pain and discolouration of his right foot. There was no relevant past medical history. He smoked 40 cigarettes a day and it was noted that his daughter had bought two zebra finches a few weeks previously.
On examination relevant clinical findings were that he was apyrexial with a regular pulse of 100 beats/min and blood pressure was 110/80. Heart sounds were normal with no murmurs. There was decreased air entry over the base of the left lung. He had bilateral palpable femoral pulses with absent right popliteal, dorsalis and posterior tibial pulse. The right foot was mottled and cold.
Relevant investigations on admission included haemoglobin 12.6 g/dl, white cell count 9.9x 10 9 11. ECG showed a normal sinus rhythm and chest X-ray showed pulmonary consolidation in the left mid-zone ( Figure 1 ). An urgent arteriogram was performed on admission which revealed a localized plaque-like irregularity in the right common iliac artery with patent femoral and popliteal arteries ( Figure 2 ). All arteries below the right knee were occluded.
recommended that renal angiography (conventionalillSA) is essential in the investigation of patients with neurofibromatosis and hypertension. A right femoral embolectomy was performed. On passing the Fogarty balloon catheter proximally, despite noting free flow, a significant amount of dark red embolic material was retrieved. Material was also retrieved from the distal vessels and the circulation restored, but the peripheral pulses did not return. The patient had been anticoagulated using heparin intravenously and later changing to warfarin. Serial bloodcultures and MSU were negative. However viral titres showedpresence of psittacosis antigen. Psittacosis titres were 1/512, 1/256, 1/128 and 1/64 at days 4, 7, 14 and 28, respectively, after admission. An echocardiogram failed to show an embolic source. Erythromycin to which C. psittaci is sensitive was used to replace cefuroxime and metronidazole. Histopathological examination of the embolic material showed a moderate amount ofpolymorphs, platelets and fibrin but no organisms. Sections from the paraffin block of the embolus were examined by indirect immunofluorescence but no psittacosis antigen was detected.
Ten days after admission the circulation in the right lower leg deteriorated, re-exploration was unsuccessful and eventually necessitated an above knee amputation which healed well. At 2 years follow-up the patient has had no further complications.
Discussion
The diagnosis of psittacosis in this patient was based on the high titres of the psittacosis complement fixation test and of the exposure to birds. The patient's relatives soon had the birds destroyed and so we were unable to say for certain whether the birds were infected. The reported incidence of psittacosis is rising"?", with many patients having no relevant 'bird contact' history. Pigeons are a major reservoir of the infective agent", Psittacosis usually has a prodromal illness with malaise, muscle aches and headaches but there was no such prodromal illness in our patient. Infection may range from subclinical to severe systemic illness", Chlamydiae are recognized as potential cardiovascular
Meeting reports
Journal of the Royal Society of Medicine Volume 84 June 1991 375 pathogens and are implicated in various acquired valvular heart diseases". This is the only reported case to our knowledge in which a major arterial embolism has occurred without cardiac involvement being detected -negative blood cultures, normal ECG and echocardiograms. It is possible that the focus of the embolus to the leg originated from the heart, but our investigations were unable to absolutely confirm this. However we know from the documented literature that arterial embolism does occur with psittacosis. 
Innovative versus generic medicines
Keywords: new chemical entities; generic medicines; regulatory affairs; product licensing; bioequivalence The debate about prescribing by brand or generic name has been a major issue for 40 years and it seems unlikely to wane, because of what has been termed the 'politics of prescribing'1. The issue is not as simple as is encapsulated in the quotation: 'There is everything in a name. A rose by any other name would smell as sweet, but would not cost half as much during the winter months.'
George Ade
This meeting of the Library (Scientific Research) Section was convened to examine some of the medical, marketing and regulatory aspects of innovative, and by implication patented, medicines and generic preparations.
Quality, safety and efficacy
The first speaker Dr Elliot Brown (Glaxo Group Research, Greenford) was given the difficult task of dealing with the quality, safety and efficacy of generic and proprietary medicines, perhaps because of his former experience with the Medicines Control Agency. He chose to confine his remarks largely to the situation in the United Kingdom, although he recognized, and referred to, the issue of generic substitution in the USA.
The issue of quality, safety and efficacy turns on the supposition that the original proprietary medicine sets the standard against which generic substitutes are compared. This is not an unreasonable premise since the research and development which determined the standard and which led to the original licence being granted would have been done with the innovative medicine. If one accepts the innovative medicine as having set the standard, the question can then be distilled into its three fractions: is the standard of the generic medicine adequate?; is it similar to the principal proprietary medicine?; and does comparability matter? If one accepts the principles ofthe Hippocratic Oath, and especially primum non nocere, then it is the third of these elements which is important.
The quality of a generic medicine is determined by the appropriate monograph in the British Pharmacopoeia, by the requirements of the Medicines Act and by EEC regulations. Specifications for the source and purity of starting materials, the route and method of synthesis, intermediate chemicals, formulations, limits of variation; stability and packaging are covered in these monographs and regulations. However, pharmacopoeial limits for control of substance and of impurities are not so narrow as to preclude some variability which might affect the clinical response, particularly if the therapeutic margin of the medicine is narrow.
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